However, some individual individuals experienced an ongoing remission of up to 9 weeks at the time of last follow-up. Open in a separate window Figure 2. Multivariate analysis of risk factors for substandard outcome. of pola bridging and successful CAR T-cell therapy resulted in a 6-month OS of 77.9% calculated from pola initiation. Pola vedotin-rituximab […]